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Abstract
Bacteria are the microorganisms that most frequently cause infectious diseases in humans. 
The synthesis of silver nanoparticles (AgNPs) has attracted interest due to the new and 
different physical and chemical characteristics with applications in new fields. AgNPs, 
alone or supported on ceramic, are used as antimicrobial fillers in textiles and polymers 
for food-packaging and biomedical applications, for antimicrobial paints, and potentially 
for drug delivery. The evaluation of mesoporous nanostructures or nanocomposites as 
FDU-12/lignin/silver was effective in inhibiting Staphylococcus aureus, E. coli, Enterococcus 
faecalis, and Candida albicans. The best results were achieved against the inhibition of 
E. coli and with the structures FDU-12/silver. In plates with FDU-12/lignin/silver,  FDU-12, 
FDU-12/lignin, and the positive control, it was enumerated at 0, 6, 14, and 27 colonies, 
respectively. While the development of resistance to a new antibiotic is expected, the 
time course and degree of resistance are uncertain and depend on various factors. The 
application of AgNPs as nanocomposites can alter the expression of bacterial proteins 
and could be used for inactivation. This review explores such aspects and a number of 
factors arising like the use of nanostructures against E. coli, from the knowledge acquired.
Keywords: Escherichia coli, nanostructures, nanocomposites, FDU-12/lignin/silver, E. coli 
resistance
1. Introduction
Bacterial survival and persistence in an inappropriate substrate can be defined as the ability 
of bacteria to tolerate exposure to lethal concentrations of bactericidal antibiotics. This view 
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was first noticed in 1944 regarding that treatment of cultures of Staphylococcus aureus with 
high concentrations of penicillin did not kill all the strains, and that a fraction of the order 
of 10−6 of these strains survived. Bacteria can cause frequently infections in humans, and the 
resistance to antibiotics is a primary cause of disease and sometimes death in the intensive-
care units of hospitals worldwide [1] and the cause of numerous clinical problems [2]. The 
development and increase of resistance among pathogens causing nosocomial and commu-
nity-acquired infections are known to be associated with the widespread utilization of anti-
biotics [3–5].
Antimicrobial is a general term for drugs, chemicals, and/or other substances that either kill 
or slow the microbial metabolism. Various antimicrobial agents that are in use today are anti-
biotic, antiviral, antifungal, and antiparisitic drugs. An antibiotic is a type of antimicrobial 
agent produced by a fungi or a bacterium that has a direct influence on other microbes, spe-
cifically bacteria. Many of antibiotic resistance genes are found on transposons, integrons, 
and/or plasmids that can be transferred to another bacteria belonging to the same or different 
species [6] and resistance elements can be transferred to the human commensal or pathogenic 
microbiome [7].
The genes conferring resistance to antibiotics have been widely distributed in the environ-
ment since before the introduction of antibiotic chemotherapies, but human activities are 
probably the major driven force of the resistant bacteria found in air and water, principally 
with S. aureus and E. coli isolates. The antibiotic presence in the environment can exert selec-
tive pressure on the organisms living closely, but the mechanisms of cross resistance to anti-
biotics are unknown [6].
Studies with animals [8] showed that the proximity with humans has the tendency to generate 
more antibiotic-resistant enteric bacteria as saw with African baboons. With birds, a study [9] 
showed that 8% of E. coli isolated from arctic region presented resistance. This can enhance 
the pressure of antibiotic resistance by an anthropogenic activity. In pristine environments, 
the determinants of an antibiotic resistance existed naturally and were probably subjected to 
horizontal gene transfer [10]. This predisposition for the genetic exchange of resistance ele-
ments has facilitated the antibiotic resistance in pathogenic bacteria.
Antibiotics kill or inhibit bacteria that are susceptible to that antibiotic. Bacteria that 
are intrinsically resistant or that can acquire resistance will survive and replace the 
 drug- susceptible bacteria. The production of an antibiotic is associated with the presence of 
genes encoding one or more self-protection processes. Antibiotic biosynthesis gene clusters 
that encode resistance proteins specific to the compound made (modification of the com-
pound or target) or multifunctional (efflux systems) are important systems. The resistance 
genes that are contiguous with the biosynthesis genes could be involved in regulation of 
the biosynthetic pathway.
There are consistent results [11] that showed that antibiotic resistance genes are found in 
natural sources. Another form of resistance in isolates not producing antibiotics is the muta-
tion of the target gene product, which reduces or prevents inhibition by antibiotic binding. 
Spontaneous mutations causing resistance often lead to different bacterial phenotypes.
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The presence of antibiotic resistance strains in environment may be understood as a response 
to the selective pressures. Thus, any antibiotic use will provide a selective pressure that per-
petuates resistant bacteria. The introduction of antibiotics in the treatment of diseases that 
were prior incurable, enabled the effective treatment of these, promoting the increase in lon-
gevity. This kind of medicine is widely used in the treatment of people in the community 
and health services and is also used to treat animals in agricultural environments. Thus, the 
increasing levels of resistance are compromising the effectiveness of them. Therefore, it is 
essential that we assess the use of antibiotics carefully, regardless of setting, and use them 
only when necessary, to avoid promoting the development of resistance among bacteria [12].
Various infections are caused by important pathogens, such as Staphylococcus aureus, and up 
to 50% are resistant to stronger drugs, such as methicillin [13], and with E. coli [12, 14–16] the 
resistant trait is growing.
The food supply can be a source of antimicrobial-resistant and virulent E. coli strains that 
could be lethal to humans or, in a major scale, can cause intestinal as well as extra intesti-
nal infections. Escherichia coli (Figure 1) is a ubiquitous and versatile microorganism, moving 
from commensal to opportunistic and specialized virulent bacteria, with potential to cause 
different diseases. To cause infection, harmless commensal E. coli can acquire a set of combi-
nation of mobile genetic elements to become a highly adapted pathogen capable of causing 
different diseases in different hosts, ranging from gastroenteritis to extra intestinal infections 
of the urinary tract, bloodstream, and central nervous system. Seven diarrheagenic and two 
extra intestinal E. coli pathovars can cause disease in various hosts.
Interestingly, one outbreak happens, caused by one not expected E. coli pathotype [18] in 2011. 
An uncommon high number of haemolytic uremic syndrome (HUS) cases were reported in 
Figure 1. E. coli in scanning electronic microscopy [17].
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Europe, most precisely in Germany. The implicated agent was an enterohemorrhagic E. coli 
(EHEC), which presented virulence traits of both, a verotoxigenic E. coli (VTEC) and enteroag-
gregative E. coli (EAEC).
A relevant study involving enterotoxigenic E. coli STb toxin was conducted in 2014 [19], 
regarding the STb toxigenicity. STb is a heat-resistant toxin responsible for diarrhea in farm 
animals and in humans as well. The toxic effect of STb in host cells is due to allowing the pas-
sage of electrolytes and water through the paracellular space. The authors [19] demonstrated 
that STb could promote the delocalization of transmembrane proteins such as claudin-1.
This event among others can prove how the versatility of this bacterium can reach a world-
wide proportion, with a high concern for public health. These types of outbreaks are not 
solely a consequence of health conditions in developing countries. With the increase in inter-
national travel and trade globalization, diarrheagenic E. coli has become a worldwide public 
health threat [20].
On the other hand, antibiotic resistance rates in E. coli are rapidly rising, especially concerning 
to the use of fluoroquinolones and third- and fourth-generation cephalosporin. These strains are 
acquired predominantly in the community [12]. In these conditions, drug-resistant E. coli are read-
ily acquired via the consumption of contaminated food and beverage. Some authors [14] studied 
287 E. coli samples isolated from meats regarding their virulence factors. They observed that drug-
resistant isolates had similar characteristics to those collected from the same types of meat.
This review shows the immune view of E. coli, and focus on the presence of these bacteria 
highlighting the acquisition of resistance and discussing various aspects of E. coli pathot-
ypes. Because the antibiotic treatment is our primary method of threaten diseases, studies 
on this field are important to a better understanding of bacterial evasion, circumventing, and 
 subverting mechanisms to acquire resistance characteristics.
2. Immune view
A good immune system is essential for the survival of any organism because of the protec-
tion against infectious beings. It is the principal infections evolution blocker that may cause 
elevated decease rate. This is a well-established fact for almost all known infective illness; 
the number of subjects in contact with the infectious agents is greater than those who really 
evolve diseases.
Contaminations occurred by no cell invasive bacteria are the most common. In these cases, the 
immune system of shield is mostly associated to the harborer’s innate barriers, natural protec-
tion mechanisms, and antibody production. The importance of innate barriers (Table 1) in the 
combat against no cell invasive bacterial infections is well-known [21]. The integrity of skin 
and mucosa prevent adherence and penetration of bacteria; mucociliary movement eliminates 
bacteria from the respiratory tract; the stomach’s acidic pH destroys some bacteria penetrating 
by the upper digestive tract; and in the saliva, eyes secretion, and prostatic secretion, lysozyme 
and other substances have antimicrobial activity.
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On the other hand, the main characteristic of intracellular bacteria is the ability to survive within 
the macrophages. In this context, some important pathogens are L. monocytogenes, Mycobacterium 
tuberculosis and, M. leprae. Invasion of the macrophage is also a parasite’s getaway strategy. 
Though paradoxical, the last mechanism is benign to the harborer, while the lack of cell penetra-
tion by bacteria can induce a strong inflammatory effect and excessive injury to the host.
Adaptive immunity, principally by means of antibodies plays an important function versus 
bacteria outside of the cell. Antibodies may exert its inhibition in three steps: (i) opsonization, 
(ii) activation of the complementary system, and (iii) furthering the neutralization of bacteria 
or their metabolites.
Extracellular bacteria are prone to undoing when phagocytozed. So subverting this system, 
they developed substances such as evasive mechanism with an antiphagocytic system.
Antibodies directed against these substances not only avoid their action, also facilitate phago-
cytosis, while neutrophils and macrophages have receivers for the fc part of immunoglobulin 
(opsonization).
The antibodies also coassist in the destruction of complement by bacteria, and activate this 
system by the classical pathway. Through neutralization mechanism, IgA antibodies, in par-
ticular, can bind to bacteria and therefore prevent the latter from settling on the intestinal 
mucosa and the respiratory tract. Antibodies bind frequently to toxins produced from bac-
teria, such as tetanus (Clostridium tetani) and diphtheria toxin (Corynebacterium diphtheriae), 
and neutralize the action of these metabolites. The fine balance between health and disease is 
found in this scenario, in which deficiency is as much as excess may result in tissue damage.
3. E. coli antibiotic resistance
A mature human gut harbors a vast number of bacterial resident microbiota, accounting for 
more than 1014 individual bacteria. Notably, the composition of the microbiota is  individual 
host specific and the type of species living in the gastrointestinal tract varies with the host 
age, diet, habits, health, and idiosyncratic status [22]. The intestinal mucosa is a first  contact 
between the immune system and the external environment and plays a central role in a 
I. Natural barriers against infection II. Innate immunity III. Acquired immunity
1. Integrity of skin and mucosa 1. Extracellular molecules (C reactive 
protein, complement)
1. Antibodies
2. Mucociliar movement 2. Natural killer cells, neutrophils, 
macrophages
2. Cytokines produced by T cells
3. pH variations 3. Chemokines, cytokines –
4. Antimicrobial substances – –
Note: Ref. [21] with modifications.
Table 1. Barriers against infectious microorganisms.
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microbe and host cross talk [23]. The indigenous intestinal microbiota provides important 
protective, metabolic and trophic functions, principally offering resistance to colonization by 
exogenous microorganisms, and preventing invasion by incoming pathogens.
The intestinal epithelium can resist against microbial invasion, but through evolution mecha-
nisms, potential pathogenic enteric microorganisms developed strategies to circumvent and sub-
vert this strong barrier. As an initial step in the infection process, some pathogens target specific 
epithelial cell structures, as glycoprotein and glycolipid [24], which act as receptors for attach-
ment, permitting the microorganisms to exploit the underlying signal transduction pathway.
Other strategies utilized by invasive pathogens such as Salmonella enterica serovar, S. thy-
phimurium, Shigella spp., and invasive E. coli orchestrated their entry into intestinal epithelial 
cells. This strategy uses the expression of a bacterial type III protein secretion system, to deliver 
various effectors proteins into the host cell [25]. This effectors protein subverts normal host cell 
processes by triggering a marked rearrangement of the host cytoskeleton. This procedure facili-
tates the pathogen to cross the epithelial barrier and induces an inflammatory host response [25].
The latter strategy can be done by direct cytotoxic injury, intracellular migration, disruption 
of the epithelial tight junctions, or indirectly by inducing neutrophil infiltration. Pathogenic 
E. coli have been shown to increase chloride ion secretion from intestinal epithelia by upregu-
lating the expression of the receptor for the neuropeptide galanin-1 [26].
Enteric pathogens have the propriety to perturb the intestinal epithelial barrier and impact paracel-
lular permeability, most often with an alteration in the arrangement of tight junctional component 
proteins by mechanisms that are unique for different pathogens. With respect to enteropatho-
genic E. coli, they disrupt the epithelial barrier by the phosphorylation of myosin light chains [27].
E. coli isolated from human and animal gut, and as well as from environmental sources 
 presenting antibiotic resistance is a public health problem, especially in developing countries 
[28]. Work conducted in 2005 [29] showed that extended spectrum lactamase producing E. coli 
(ESBL) strains have spread as a hospital infection. The large plasmid genes coding this resis-
tance also carry genes for resistance to other antibiotics [30]. The frequency of resistance to 
fluoroquinolone antibiotics (ciprofloxacin, levofloxacin, moxifloxacin, norfloxacin, and nali-
dixic acid) in E. coli has increased worldwide [31].
In one review about E. coli producing fimbrial or afimbrial adhesins [32], authors showed 
that some E. coli strains (ETEC STb positive) associated with diarrhea, presented an afimbrial 
adhesin, named AIDA-I (adhesion involved in diffuse adherence). This adhesin originally 
found in human E. coli isolates showed that the establishment of a persistent and chronic 
infection could also help the microorganism to resist antimicrobial agents and prevent effec-
tive treatment of diseased animals.
In 2010, some authors [33] detected high resistance rates among E. coli (up to 30%) to ampicil-
lin, tetracycline, streptomycin, ciprofloxacin, enrofloxacin, and cotrimoxazol. These authors 
[33] also found lower resistance to gentamicin (6.5%) and chloramphenicol (3.2%).
Also in 2010, one study [34] reported that morbidity and mortality attributable to  third 
-generation-cephalosporin-resistant E. coli are significant. They also believe that if  prevailing 
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resistance trends continue, high societal and economic costs can be expected and that better 
management of infections caused by resistant E. coli is becoming essential.
Work with neonates in a single center concluded that the use of minor antibiotic therapy with 
reducing preemptive treatment resulted in a moderate reduction of the antibiotic use and did 
not increase mortality [35].
Another study [36] was conducted to determine the antimicrobial susceptibility pat-
terns among common pathogens in the intensive care unit of a university hospital in Iran 
between 2006 and 2009. Authors worked with 606 isolates from respiratory, urine, blood, and 
wound specimens of 456 patients. E. coli was present in 8.3% of isolates, and presented high 
 antimicrobial resistance.
Scientists worked with 1163 clinical isolates in Taiwan [37]. The frequencies of Gram-positive 
and Gram-negative bacteria isolates were 30.4 and 56.2%, respectively. Staphylococcus aureus 
was the most common isolate among the Gram-positive organisms, while Pseudomonas aerugi-
nosa, E. coli, and Klebsiella pneumoniae were the leading Gram-negative isolates.
The antimicrobial resistance in one intensive care unit in Canada was investigated. In 2008, it 
was found high antibiotic rates to E. coli: cefazolin, 20.1%; cefepime, 0.7%; ceftriaxone, 3.7%; 
gentamicin, 3.0%; fluoroquinolones, 21.1%; piperacillin-tazobactam, 1.9%; and trimethoprim-
sulfamethoxazole, 24.8%. E. coli was the most prevalent Gram-negative bacterium [38].
According to a work conducted in 1975 [39], a hospital acquired urinary tract infection account 
for approximately 45% of nosocomial infection and 2–4% of the cases may develop septice-
mia. In this context, it was observed that 40% of the Gram-negative septicemia acquired in 
hospital originates in the urinary tract. This observation can enhance the E. coli importance 
for acquiring resistance. In 2009 was observed that, Gram-negative bacteria were the most 
frequent isolates, with E. coli being the most common followed by Pseudomonas aeruginosa 
and Klebsiella spp. Candida albicans accounted for almost 11% of the organisms, followed by 
Acinetobacter baumanni (Table 2) [39].
Bacteria and fungi Total Resistance to all Sensibility
N (%) N (%) N (%)
Escherichia coli 27 (49.1) 22 (81.5) 5 (18.5)
Pseudomonas aeruginosa 7 (12.7) 5 (71.4) 2 (28.6)
Klebsiella spp. 7 (12.7) 4 (57.1) 3 (42.9)
Candida albicans 6 (10.9) – –
Acinetobacter baumanni 3 (5.5) 3 (100) 0
Others 5 (9.1) 2 (40) 3 (60)
Total 55 (100) 36 (73.5) 13 (26.5)
Note: Ref. [39] with modifications.
Table 2. Profile resistance of main microorganisms isolated from hospitals.
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4. Mechanisms of antibiotic resistance in Gram-negative bacteria
Bacterial antimicrobial resistance in both the medical and agricultural fields has become a 
serious problem worldwide. Resistant bacteria isolated from agriculture, farm or hospital 
can transfer the resistance genes to human pathogens [40]. The selection pressure applied 
by the antibiotics that are used in clinical and agricultural settings has promoted the evolu-
tion and spread of genes that confer resistance, regardless of their origins. Several factors 
can be implicated with resistance, sensibility, and antibiotic resistance dissemination such 
as: (i) impermeable barriers [6]; in this case, some bacteria are intrinsically resistant to certain 
antibiotics because they have an impermeable membrane or lack the target of the antibiotic; 
(ii) multidrug resistance efflux pumps; these pumps protect the bacterial cell against toxic 
molecules. It is an active transport mechanism for outside the cell. Some transporters, such as 
those of the resistance-nodulation cell division family, can pump antibiotics directly outside 
the cell, whereas others, such as those of the major facilitator superfamily, secrete them into 
the bacterial periplasm; (iii) resistance mutations; these mutations can cause a modification in 
the target protein, for example, by disabling the antibiotic-binding without changing the pro-
tein functionality. Specific examples include mutations in the gyrase, which cause resistance 
to fluoroquinolones, in RNA polymerase subunit B, which cause resistance to rifampicin, and 
in the 30S ribosomal subunit protein S12 (encoded by rpsL), which cause resistance to strepto-
mycin; and (iv) antibiotic inactivation; inactivation can occur by covalent modification of the 
antibiotic, such as that catalyzed by acetyltransferases acting on aminoglycoside antibiotics, 
or by degradation of the antibiotic, such as the hydrolytic degradation of the β-lactam ring on 
antibiotics by the β-lactamases. The emergence of drug resistance among diarrheagenic E. coli 
is important, and in infant, is a cause of morbidity and mortality principally in developing 
countries. Analyzing stools of infants in India was verified that about 90% of E. coli strains 
presented resistance to the most antibiotics tested [41]. All isolates were resistant to ampicil-
lin, imipenem, cotrimoxazole, and sensitive to amikacin, and presented 29 different antibiotic 
profiles. Most of the isolated E. coli harbored plasmids (64%) and up to 76% could transfer 
their plasmids. The transconjugant strains were carrying plasmids and presented resistance 
to ampicillin, imipenem, and cotrimoxazole. The authors found an increase in the prevalence 
of drug resistance among E. coli isolates, and conjugation transfer of plasmids contributed to 
a rapid spread of an antibiotic resistance.
Cyclomodulins are a growing functional family of toxins, which hijack eukaryotic cell cycle. 
Four cyclomodulin types are actually known in E. coli: cytotoxic necrotizing factors (CNFs), 
cycle inhibiting factor (Cif), cytolethal distending toxins (CDTs), and the pks-encoded toxin.
One interesting work [42] isolated ceftriaxone-resistant E. coli from 1.5% of participants in 
Maryland and Michigan, United States. One E. coli isolate collected from an apparently healthy 
person, presented resistance to eight antibiotics, and the resistance genes were contained on 
an incompatibility plasmid. These plasmid types are common among Enterobacteriaceae and 
can carry multiple resistance genes, generating multidrug resistance [43]. In Krueger’s work 
[42], the source of the extensively resistant E. coli is not known, but the isolated strain may 
have been acquired from food.
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5. Diarrheagenic and extra intestinal E. coli pathotypes
Several distinct pathogenic categories (i.e., pathotypes or virotypes) of diarrheagenic E. coli 
strains are recognized. Each pathotype is defined by a characteristic set of virulence-associ-
ated determinants that act in a concert to determine the clinical, pathological, and epidemio-
logical features of the disease they cause [44].
By definition, the virulence determinants of each E. coli pathotype are distinct. However, they 
can generally be categorized as either colonization factors (adhesins), which enable the bacte-
ria to bind closely to the intestinal mucosa and resist removal by peristalsis, or secreted tox-
ins, which interfere with the normal physiological processes of host cells. The key virulence 
determinants of the primary pathotypes of diarrheagenic E. coli are summarized in Table 3.
Pathotype Common genotype Most common 
presentation
Intestinal pathology Susceptibile groups
EPEC eae +, bfp +, EAF + Non-specific 
gastroenteritis, 
noninflammatory 
diarrhea
Intimate adhesion, 
attaching–effacing 
lesions throughout 
the intestine, loss 
of brush border 
enterocyte
Children under 
2 years of age in 
developing countries
ETEC LT, ST, (STa, STb 
toxins)
Watery, cholera-
like diarrhea, 
noninflammatory 
diarrhea
No notable change, 
adhesion to small 
intestinal mucosa
Children in 
developing countries; 
travelers
EHEC eae +, stx + Bloody diarrhea 
‘Hemorrhagic colitis’;
attaching–effacing 
lesions confined to 
the large intestine; 
necrosis in severe 
cases; HUS, 
hemorrhagic colitis
Children and 
the elderly in 
industrialized 
countries
EIEC Inv Bacillary dysentery Inflammation and 
disruption of the 
mucosa, mostly of 
the large intestine; 
necrosis and blood 
loss
All ages; more 
common in less-
developed countries
EAEC AA +, aaa −/aaa + Persistent diarrhea 
Inflammation;
cytotoxic changes in 
enterocytes
Children in less-
developed countries; 
travelers to those 
countries
A-EPEC eae +, bfp (−/+), EAF − Nonspecific 
gastroenteritis
Some lesions 
throughout the 
intestine; toxin 
production as EAST1
Children and adults; 
reservoir for human 
infection
Note: Ref. [44] with modifications.
Table 3. Key virulence determinants of diarrheagenic E. coli.
Antibiotic Resistance among Escherichia coli: Isolates and Novel Approaches to the Control of E. coli Infections
http://dx.doi.org/10.5772/67400
107
It can be seen in Table 3, that the number of virulence traits varies from each pathotype and 
have implications on intestinal pathology. Besides Enteropathogenic E. coli (EPEC)  causing 
intimate adhesion, attaching-effacing lesions throughout the intestine and loss of brush 
enterocytes, Enterotoxigenic E. coli (ETEC) do not present notable change to intestinal mucosa. 
Enterohaemorragic E. coli (EHEC) provoke a similar intestinal pathology, with necrosis. 
Enteroinvasive E. coli (EIEC) cause inflammation and necrosis, but Enteroaggregative E. coli 
(EAEC) present enterocytes changes. Atypical E. coli (A-EPEC) and Diffusely adherent E. coli 
(DAEC) can cause lesions in the intestine.
Based on genetic variation within E. coli, it was found [45] that pathogenic strains have acceler-
ated the rates of mutation and recombination and virulence is the driving force for more fre-
quent recombination. These characteristics can impulse the bacterial population to acquire more 
resistance. Some studies [45–46] proposed a model where commensal E. coli maintains low fre-
quencies of homologous recombination and acquisition of novel genes that result in virulence 
by horizontal genetic exchange. The pathogenic condition results in exposure to immune system 
barriers and antibiotic selection. These population presents higher mutation and recombina-
tion rates. Epidemic strains are exposed to stronger selection by pressures imposed by immune 
defenses and antibiotic use, resulting in highest levels of mutation, recombination, and infection.
In one study, conducted in Ontario, Canada, the authors [15] showed that the most com-
mon bacteria identified on urine culture over a 5 year period were Escherichia coli (71.6%), 
Enterococcus spp. (5.7%), and Klebsiella spp. (5.0%) and that these bacteria were frequently 
resistant to ampicillin (54.4%) and trimethoprim-sulfamethoxazole (TMP-SMX) (40.4%) [15].
Another study showed that resistance was more commonly seen in typical EPEC than in 
atypical pathotypes. The most prevalent resistances observed were to ampicillin, tetracycline, 
streptomycin, and the sulfonamides [16].
EPEC, an established etiological agent of human infantile diarrhea, is a pathogen that subverts 
intestinal epithelial cell function to produce distinctive “attaching and effacing” (A/E) lesions. 
These types of pathogens are typically found on the surface of the host epithelial cell. They can 
cause severe lesions on intestinal microvilli. Other pathogens can display similar characteris-
tics, which includes Hafnia alvei, Citrobacter rodentium, and enterohemorrhagic E. coli.
The interactions between EPEC and host cells have been divided into three stages. Initial adher-
ence to cultured epithelial cells is mediated by the formation of type IV fimbriae known as bun-
dle forming pili (BFP) [47]. Initial adherence helps bring the bacteria in intimate contact with 
the host cell. BFPs mediate bacterial interactions in a human intestinal organ culture model [48].
The genetic answer for the formation of A/E lesions can be explained by the presence of the locus 
of enterocyte effacement (LEE) [49]. This cluster includes the genes of following bacterial proteins: 
E. coli attaching and effacing that encodes the protein intimin (eae); E. coli secretion (escs); E. coli-
secreted protein (esps); secretion of E. coli proteins (sep), and translocated intimin receptor (Tir).
The second stage of EPEC pathogenesis involves the secretion of bacterial proteins, some 
into the host cell, including EspA, EspB, and EspD at the temperature of the body [50], and 
 particularly the gastrointestinal tract, the expression of these proteins is maximal, which 
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implies that they may be involved in virulence. The translocation of these proteins is essential 
for activating a number of signal transduction pathways.
The third stage of EPEC interaction with the eukaryotic cells is characterized by the intimate 
attachment with the host cell. A 94-kDa outer membrane protein and intimin, encoded by the 
eae gene [51], binds to a 90-kDa tyrosine phosphorylated protein in the host membrane. This 
receptor is of bacterial origin and has been designated as the translocated intimin receptor 
(Tir). Tir is translocated from the bacterial cell into the host membrane, where it becomes phos-
phorylated on one or more tyrosine residues and functions as a receptor for its binding partner, 
intimin. The resultant tight association is accompanied by the formation of actin pedestals. The 
most remarkable change in the cellular structure of the eukaryotic cell is the formation of typi-
cal actin pedestals. Within 3 hours of infection by EPEC, host-cell actin, a-actinin, talin, erzin, 
and villin accumulate directly under the bacteria. EPEC presents a strong and intimate adhe-
sion to the intestinal mucosa leading to dissolution of the brush border by inducing vesicula-
tion of the microvilli. This is the attaching and effacement step, and in the jejunum and ileum 
results in a loss of brush border disaccharidase enzymes and a large area of absorptive surface.
Typical kinds of EPEC are EPECs that have lost the EAF plasmid. ETEC strains are a major 
cause of secretory diarrhea in both humans and animals. They produce heat-labile and/or heat-
stable (STa and STb) toxins that also cause diarrhea. EHEC strains are implicated in foodborne 
diseases principally due to ingestion of uncooked minced meat and raw milk. These strains 
produce shiga-like toxin 1 (stx1), shiga-like toxin 2 (stx2), and variants thereof. These toxins 
can destroy colonic enterocytes and produce hemorrhagic colitis. EIEC can attach to entero-
cytes and penetrate by endocytosis and replicate therein. DAEC strains are diffusely adhering 
E. coli that are also implicated with episodes of diarrhea. EAEC damage and blunt colonic villi 
by hemorrhagic necrosis, although the precise pathogenic mechanisms are unclear. EAEC are 
a major cause of chronic diarrhea in children. ExPEC are the cause of a diverse spectrum of 
invasive human and animal infections, often leading to septicemia and sometimes to death.
Extraintestinal E. coli (ExPEC) strains have amazing behavior and possess virulence mecha-
nisms to invade, colonize, and induce disease in sites outside of the gastrointestinal tract. 
Human diseases caused by the ExPEC include urinary tract infections, neonatal meningitis, 
sepsis, pneumonia, surgical site infections, as well as infections in other extraintestinal loca-
tions. ExPEC strains have been isolated from food products, in particular from raw meats, 
and poultry, indicating that these organisms potentially represent a new class of foodborne 
pathogens [52–53].
Extraintestinal E. coli infections are associated with specialized strains presenting antimicro-
bial resistance. The food supply may disseminate ExPEC and antimicrobial-resistant E. coli. 
Retail foods may be an important vehicle for community-wide dissemination of antimicro-
bial-resistant E. coli and ExPEC, which may represent a newly recognized group of medically 
significant foodborne pathogens.
E. coli contamination exhibited a prevalence gradient from miscellaneous foods (9%), through 
beef or pork (69%), to poultry (92%) [54]. Among E. coli-positive samples, similar prevalence 
gradients were detected for antimicrobial resistance (27, 85, and 94 of samples, respectively) 
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and ExPEC contamination (4, 19, and 46%, respectively). Indirect evidence suggested on-farm 
selection of resistance.
Uropathogenic strains can invade bladder cells and at this local, form reservoirs, which is 
possibly the storage local of the bacterium. E. coli causing infant meningitis is resistant to 
host immune responses and has the ability to cross the blood-brain barrier and cause disease. 
ExPEC from human and avian hosts encounter similar challenges in establishing infection in 
extraintestinal locations.
Extended spectrum beta-lactamases (ESBLs) are the bacterial enzymes that make them resis-
tant to advanced generation cephalosporins and might lead to the failure on therapy.
The importance of this resistance in one children population in India was studied. CTX-M-
15 enzyme is increasingly being reported from this part of the world together with TEM-1 
[55]. TEM-1 is the most commonly encountered beta-lactamase in Gram-negative bacteria. 
Up to 90% of ampicillin, resistance in E. coli is due to the production of TEM-1 and E. coli is 
the most common cause of neonatal sepsis. The authors found that 97 ESBL-producers were 
identified among 266 E. coli strains isolated from 238 neonates. The isolates were screened for 
blaCTX-M, blaTEM, armA, rmtA, and rmtB, the last three genes being responsible for ami-
noglycoside resistance. The authors [55] concluded that male neonates colonized or infected 
by ESBL-producing E. coli have longer stay in NICU compared to their female counterparts. 
This happened because of male neonates getting colonized and/or infected earlier than their 
female counterparts do. Plasmid-mediated-conjugal transfer was found to be the mechanism 
of transfer of blaCTX-M-15 resistance marker in the described setting [55].
Antimicrobial drug resistance is a large and growing problem among organisms that cause 
diarrheal disease. Although most diarrheal diseases are self-resolving and should not be 
treated with antimicrobial agents, invasive or protracted infections require chemotherapy and 
are typically managed empirically [56].
The more recently defined enteroaggregative E. coli are typically multidrug-resistant and are 
one of the most common causes of childhood diarrhea, particularly persistent infections [56]. 
Antimicrobial drug-resistant diarrheagenic E. coli pathotypes, including enteroaggregative E. coli, 
are also emerging as important diarrheal pathogens in AIDS patients [57].
According some data [18, 20] about E. coli outbreaks, new pathotypes can emerge and cause 
disease and death in different populations in both, developed [20] and in developing [53] 
countries. Other authors [58] observed that both EHEC O157 and non-O157 STEC infections 
can occur at the same time. These authors presented some interesting reasons to this, such as: 
(i) they are common and may be increasing in frequency; (ii) could be associated with high 
morbidity and mortality; (iii) utilizing ideal laboratory conditions these pathogens should be 
detected by both, culture procedures and using protocols to detect Shiga toxin; and (iv) these 
strains cannot be readily detected with certainty by selective targeting of patients age, time of 
year or presence of blood in the stool. These observations can be understood in a globalized 
world. Humans are embedded into the microbial world.
In healthy populations, saprophytic microorganisms constitute a rich source of genetic material 
which pathogens can readily acquire resistance. The study conducted by NIS in Nigeria showed 
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that resistance of commensal E. coli to almost all agents studied increased rapidly over time [59]. 
Additionally, urban residents in Nigeria, Ghana, and Zimbabwe were more likely to carry mul-
tidrug-resistant E. coli than were rural or provincial residents [60]. This finding has important 
consequences in light of the rapid rate of urbanization in these countries and other parts of the 
continent. Travel networks have become more efficient and are more extensively used.
Most antibiotic-producing strains carry genes encoding resistance to the antibiotics that they 
produce, and they are located in the same gene cluster as the antibiotic biosynthesis pathway 
genes. The sources by which antibiotic resistance genes can be found are presented in Table 4.
Resistance genes exist naturally in the environment owing to a range of selective pressures 
in nature. Humans have applied additional selective pressure for antibiotic resistance genes 
because of the large quantities produced, consumed, and applied in daily activities. Physical 
and biological forces also cause widespread dissemination of resistance throughout many 
natural environments.
In lifetime, humans are exposed to antibiotic resistance bacteria. The potential routes for 
human exposition with wild animals and its microbiota include [6]: (i) translocation of 
wildlife into suburban areas, habit destruction, pollution ,and changes to water storage, 
irrigation or climate changes; (ii) human contact with nature such as hunting and camping; 
(iii)  consumption of exotic foods, bushmeat and game farms; (iv) acquisition of exotic pets 
and transport of live animals from long distances; (v) incorporation of animal’s habitats in 
human life as zoos; and (vi) trapping of fur-bearing animals.
Some microorganisms and some environments harbor antibiotic resistance genes irrespec-
tive of the human use of antibiotics. The prevalence and diversity of resistance genes in the 
environment inspire hypotheses about the native roles of so-called resistance genes in natural 
microbial communities.
Selection for antibiotic resistance Environment Utilization
Nature Medicine Agriculture
Protection against endogenous 
antibiotics
Industrial antibiotic production Utilization of antibiotics onto fields
Protection against naturally 
occurring antibiotics and heavy 
metals
Antibiotic consumption Antibiotic consumption
Alternative cellular functions of the 
resistance protein
– –
Spread of antibiotic resistance genes – –
Physical forces Biological forces –
Air currents Human activities –
Water Animal presence –
Note: Ref. [6] modified.
Table 4. Sources and movement of antibiotic resistance genes in the environment.
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6. Antibiotic resistance requires a coordinated response
Antibiotic use in animals has led to the emergence of resistant bacteria, and sometimes these 
resistant bacteria can be transferred from animals to humans by direct contact or by handling 
and/or consuming contaminated food.
High levels of resistance were observed for tetracycline as well as intermediate resistance 
against tetracycline, amikacin, and gentamicin. Gentamicin was the most effective out of these 
antibiotics [61]. Some authors [62] have showed high rates of tetracycline resistance in strains 
of enteric E. coli. Preventing resistant infections provides the greatest opportunity to limit resis-
tance. Strategies to prevent and control resistant bacteria vary by the pathogen and the setting 
in which the infection is acquired. Infections were diagnosed in 188 patients from a single 
healthcare institution [63]. The medical costs for antibiotic resistant infections were estimated 
between $13.35 and $18.75 million dollars. In United States, antibiotic resistance is also an eco-
nomic burden on the healthcare system, in other words, resistant infections cost more to treat.
Unfortunately, infections caused by antibiotic resistant bacteria are an everyday occurrence 
in healthcare settings. In United States, an effort of the National Antimicrobial Resistance 
Monitoring System (NARMS) contributes to minimize the impact of resistance. NARMS 
consists in a lab-based system for surveillance. This system is presented in all 50 states and 
detects resistance in pathogens that are commonly transmitted from animals to humans or 
through food, such as Salmonella, Campylobacter, and E. coli. Outbreaks caused by resistant bac-
teria can occur in community settings where people are concentrated, such as athletic teams, 
childcare centers, and prisons, or in healthcare settings, including hospitals, long-term care 
facilities, and ambulatory care facilities. Because the impact of resistance is extensive, activi-
ties may be done. The action plan could focus on: (i) reducing inappropriate antimicrobial 
use; (ii)  reducing the spread of antimicrobial resistant microorganisms in institutions, com-
munities, and agriculture; (iii) encouraging the development of new antiinfective products, 
 vaccines, and adjunct therapies; and (iv) supporting basic research on antimicrobial resistance.
Another interesting goal to the process used to inhibit pathogens is linked to ancient knowl-
edge. Many plant products are known to be able to inhibit the growth of several pathogens 
[64]. These compounds are used by plants in defense mechanisms such as predation by herbi-
vores, insects, and microbial infections.
On the other hand, some studies [65] have shown that microorganisms living in intimate 
interaction with the host plant without causing any apparent disease symptoms produce 
most of these compounds. These microorganisms are defined as endophytes [65].
Some studies [65] recently showed that the phytochemicals produced by endophytes have 
revolutionized the use of these microorganisms as a source of bioactive compounds in recent 
years [65]. Among the great diversity of the different biomes, many plants stand out for its 
medicinal properties.
Streptomyces tubercidicus can produce tubercidin. Scientists working with a strain isolated from 
the Brazilian tropical savannah tree (Solanum lycocarpum St. Hill), named this strain (RND-C) 
[66]. In this study, different fractions with strong antimicrobial activity against E. coli and 
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S. aureus were obtained. The fractions showed a diverse chemical structure and molecular 
weight, suggesting the presence of new bioactive compounds.
In another study [67], Paenibacillus polymyxa was isolated as an endophyte from Prunus spp. in 
the same environment (Brazilian tropical savannah) as S. tubercidicus. This study reported the 
isolation of potent bioactivity of small molecules (<403 Da), against E. coli and. S. aureus. The 
previous author with collaborators [68] conducted studies highlighting conditions for pro-
duction and characterization of these bioactive substances isolated from P. polymyxa RNC-D. 
Recently, a new group [69, 70] showed as well that endophytes isolated from Miconia albicans 
had that potential to inhibit E. coli and other pathogens.
According to these data, the bioprospection of endophytes consists in a promising and unex-
plored reserve for phytochemical agents. Thus, there is a great opportunity to find new anti-
microbial substances [64, 65].
7. Nanotechnology in health sciences
Nanotechnology is the technology that deals with materials and products at the nanoscale. 
It is able to provide more effective solutions to some of the biotechnology issues, such as the 
development of drugs, due to the reduction of the proportion between contact surfaces and 
volume of materials, optimizing their action and consequently reduces the consumption of 
substances and products.
Mesoporous nanostructures, as FDU-12 silica, have high specific surface area, mesoporous 
large volume, diameter, and adjustable pore surface properties that can be directed to the 
desired needs. They also have a great importance in catalysis processes, adsorption separa-
tion of large molecules, sensors, photonics, optical, drug release or drug, acoustic, nanoreac-
tors, nanotechnology with advanced integrated systems, among others [71].
Lignin, besides being the second vegetal macromolecule found naturally in abundance, can 
functionalized mesoporous nanostructures, as it has in its structure phenolic and carboxylic 
groups. These groups are still capable of reducing metal to form nanoparticles and they also 
have the advantage coat of the silver nanoparticles.
8. Nanoparticles linked to silver
Metallic nanoparticles have different functions, like the following: (i) the marking of a par-
ticular stretch of DNA; (ii) the increase in resistance of metals and in the case of nanoparticles 
linked to silver; (iii) the antimicrobial action (both against Gram-negative bacteria, which 
have a thin layer of peptidoglycan and against Gram-positive, whose layer is thicker); and (iv) 
fungicide, which makes these particles a special nanostructured material to be incorporated 
into the control of such pathogens [72, 73].
However, there are no general consensuses about the mechanisms that can explain the action 
of silver nanoparticles in the inhibition of microbial growth. Some researchers claim that  silver 
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reacts with the thiol group of some vital enzymes to microorganisms and inactive them. Others 
claim dimerization of the pyrimidines of DNA, thus preventing the replication and thus their 
growth [74]. Another hypothesis is that the silver nanoparticle causes a change in the cell mem-
brane, causing the output of reducing sugars of the membrane and thus causing cell death [75].
A study conducted by Xu et al. [76] concluded that reactive oxygen species (ROS) played a 
very important role in the mechanism of AgNPs antibacterial activity, because in anaerobic 
conditions the efficiency was significantly lower.
Recently [77], α-Ag
2
WO4 microcrystals were synthetized and tested for antimicrobial activity 
against E. coli. The successful of the inactivation was directly related to the presence of specific 
defects in crystal surfaces. This interaction crystal-bacteria leads to a production of OH* and 
O
2
H* radicals that interact with several components of bacteria such as peptidoglycan, DNA, 
cell wall, proteins, and other bacterial structures (Figure 2) [77].
Figure 2. α-Ag
2
WO4 microcrystals in FE-SEM images (a, c, e, and g) and, respectively crystal shape (b, d, f, and h). The crystals were synthetized by MH method. The points highlighted in different colors corresponds each to its respective 
crystallographic planes [17].
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It is known that silver is a toxic metal, for both humans at high concentrations, as for most 
microorganisms, it is the preferred substance for inhibition thereof, when compared to gold 
nanoparticles, zinc, and magnesium titanium [78].
The nanocomposites efficiency, containing silver, for the silver ion is much higher than the 
single metal species, as it has been proved in experiments [78]. It is not completely understood 
yet, but it is believed that connecting silver to other nanoparticles, such as silica and lignin, 
can inhibit the growth of microorganisms and these nanoparticles contribute to the destabiliz-
ing effect of the cell membrane.
9. Bioactivity of propolis nanoparticles against E. coli
Propolis is a natural resinous substance collected from the leaf buds of different tree species 
by honeybees and known for its biological properties (antibacterial, antifungal, and antioxi-
dant) [79].
Some authors [80] evaluated the antimicrobial activity of propolis nanoparticles in compari-
son with ethanol-propolis extract against E. coli. Ethanol-propolis extract was obtained from 
green propolis resin, in absolute ethanol under agitation during 15 days. To obtain the propo-
lis nanoparticles, ethanol-propolis extract at 13.75% (w/v) was mixed with polyvinyl-alcohol 
solution at 0.1% (w/v). The size of the nanoparticles was determined by dynamic light scatter-
ing (DLS), atomic force microscopy (AFM), and it was about 70 nm in average [80].
Antimicrobial activity of propolis nanoparticles and ethanol-propolis extract was tested 
against E. coli. Qualitative minimum inhibitory concentrations (MIC) of both solutions were 
evaluated by agar-well diffusion method, as shown in Figure 3. The result was 3.44% (w/v) 
for ethanol-propolis extract and 1.15% (w/v) for propolis nanoparticles.
Figure 3. Determination of qualitative MIC of propolis nanoparticles against E. coli by agar-well diffusion method in 
plate dish [80].
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The shown antimicrobial activity of propolis nanoparticles is of potential interest for direct 
applications or in film formulations, for example. Therefore, results obtained in this study, set 
the bases for future studies, using films as support for propolis nanoparticles, and for applica-
tion in many products.
10. Conclusions
In the preantibiotic era [81], it was showed that from 30 lyophilized strains before 1950, four 
were multidrug resistant. The study of bacterial resistance can contribute to the discovery 
of the potential sources and novel alleles of antibiotic resistance genes. Considering that 
antibiotic treatment is our primary, and in many cases only, method of treating infectious 
diseases. We conclude that studies of environmental reservoirs of resistance are crucial to 
our future ability to fight infection. It is important to establish measures and politics to 
control the use of antibiotics, but an immediate modification of resistant profile in bacteria 
is not expected. Patients may follow procedures and use the antibiotics according prescrip-
tion. The usual techniques of hand wash and use of barriers to prevent bacterial spread is 
important.
In the experiments, the FDU-12/silver nanoparticles showed the greatest inhibition in 
the growth of E. coli, as was observed fewer colonies or even their absence. Based on 
these results, we can infer that the best nanoparticle, among tested to inhibit the growth of 
E. coli is described above. The second nanocomposites with proven efficiency in inhibiting 
the growth of E. coli were nanoparticles containing only FDU-12, with an intermediate effi-
ciency. The last nanoparticle studied, FDU-12/lignin/silver, showed the lowest efficiency 
in inhibiting the growth of E. coli, allowing a greater number of colonies to grow in the 
culture medium.
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